Krakow, Poland – September 15, 2017 – Selvita, one of the largest drug discovery companies in Europe, has published semiannual financial results.
In H1 2017 Selvita Group recognized total operating revenues (incl. grants) of PLN 59.7 MM, which means a 109% increase compared to H1 2016 when the operating revenues amounted to PLN 28.5 MM.
Sales revenues increased in all of Selvita operating segments:
– Revenues from the services segment showed a solid increase of 31% (PLN 19.6 MM vs. PLN 14.9 MM).
– Revenues of the innovation (pipeline) segment rose very significantly by 337% (PLN 28.3 vs. PLN 6.4 MM). High dynamics of sales and operating profit in the innovation segment of the Group in H1 2017 was driven mainly by the partnering deal on SEL24 program with Berlin Chemie/Menarini.
– The bioinformatics segment has generated a 190% increase in revenues (PLN 3.1 MM vs. PLN 1.2 MM).
In H1 2017 revenues from subsidies increased by 38% in comparison to the H1 2016 (PLN 7.8 MM vs. PLN 5.6 MM).
The results show clearly that the company is growing strong across all divisions, enjoying stable and balanced business growth.
Group’s net profit amounted to PLN 8.8 MM versus PLN 0.3 MM in H1 2016.